Conjugation of Ibuprofen to Poly Ethylene Glycol and In-vitro drug release evaluation
Polymer, Conjugation, In vitro, prodrug, spacer molecule.
Polymers have become an integral part of drug delivery systems due to their improved pharmacokinetics properties. Polymer conjugation is a well-known and widely exploited technique useful to improve therapeutic properties of peptides, proteins, small molecules and oligonucleotides. Polymer conjugated drug generally exhibit prolonged half-life, higher stability, water solubility, lower immunogenicity, antigenicity and often also to the specific targeting tissue. Polymer materials are designed to be capable of delivering active substance. to the target diseased tissues and cells. Conjugation of Ibuprofen and polyethylene glycol (PEG) helps to increase the duration of action of the parent drug. The PEG-Ibu conjugates were synthesized from ibuprofen and PEG with two different molecular weights by esterification in the presence of DCC and DMAP. The PEG-Ibu conjugation characterized by FT-IR, UV, DSC and NMR and also in-vitro drug release study in different buffer at different ph.
Keyword: Polymer, Conjugation, In vitro, prodrug, spacer molecule.
2. Douša M , Meca L , Gibala P , Jirman J , Tkadlecová M , Srbek J , Šalandová J Kovalcíková, E Brichác J, Esterification of Ibuprofen in Soft Gelatin Capsules Formulations-Identification, Synthesis and Liquid Chromatography Separation of the Degradation Products ,PubMed , 2017; 55(8):790-797.
3. Nayak A , Jain A, In Vitro and In Vivo Study of Poly(ethylene glycol) Conjugated Ibuprofen to Extend the Duration of Action, Scientia Pharmaceutica , 2011 Apr-Jun; 79(2): 359–373.
4. Ozguney IS, Karasulu HY, Kantarci G, Sozer S, Guneri T, Ertan G. Transdermal Delivery of Diclofenac Sodium Through Rat Skin From Various Formulations. AAPS PharmSciTech. 2006; 7: E39-E4.
5. Zacchigna M, Luca GD, Cateni F, Maurich V. Improvement of warfarin biopharmaceutics by conjugation with poly (ethylene glycol).Eur J Pharm Sci. 2004; 23:379–384.
6. Segal Ehud, Ronit Satchi-Fainaro, design and development of polymer conjugates as anti- angiogenic agents, ELSEVIER, 2009.
7. Greco Francesca, Vicent María J, Combination therapy: Opportunities and challenges for polymer– drug conjugates as anticancer nanomedicines, ELSEVIER, 2009.
8. Pang Xin, Jiang Yue, pH-responsive polymer– drug conjugates: Design and progress, ELSVIER, 2016.
9. Shamaya Yosi, Golan Moran, Assessing the therapeutic effi cacy of VEGFR-1-targeted polymer drug conjugates in mouse tumor models, ELSVIER, 2016.
10. Rohini, Agrawal N, Polymeric Prodrugs: Recent Achievements and General Strategies, Journal of Antivirals & Antiretrovirals, 2013.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open Access).